The Monarch system means patients can get the diagnosis they need without unnecessary surgery and begin treatment at a stage when treatment is likely to be more effective.
One of the biggest challenges in treating ovarian cancer is the fact that most women are not diagnosed until the cancer has already advanced and five-year survival is around 30%. By contrast, early-stage disease is highly treatable, with a survival rate of 90%.
Researchers at Roswell Park Comprehensive Cancer Center have been actively engaged in the effort to develop treatments or other control strategies that can help communities worldwide to address the impacts of the COVID-19 pandemic.
In 2019, Pamela Hershberger, PhD, came upon a stunningly significant finding in her research lab. Dr. Hershberger, Associate Professor of Oncology in Roswell Park’s Department of Pharmacology and Therapeutics, says she and her team had been “studying patients with a particular type of lung cancer — EGFR mutant lung cancer — and their response to a specific class of drugs called EGFR tyrosine kinase inhibitors. The drugs were proving very effective in killing cancer cells, but typically lost their effectiveness after about a year.
2020 was shaping up to be a busy and exciting year for Pawel Kalinski, MD, PhD, Vice Chair for Translational Research at Roswell Park, and his team at the Center of Immunology.
What is a pulse oximeter? Your healthcare provider may have clipped this little device onto the end of your finger when you visited the hospital or your doctor’s office.
